PARP1 and small cell lung carcinoma: In SCLC, a phase II trial (NCT04701307) evaluated the efficacy of combination therapy including the anti-PD-1 monoclonal antibody dostarlimab and the PARP inhibitor niraparib in pre-treated extensive-stage patients [97].